Drug prices in the United States are not set by any single formula. They result from a layered process involving manufacturer decisions, patent protections, negotiations between middlemen, and insurance plan design. Unlike most consumer products, the “price” of a prescription drug can mean different things depending on who is paying, with list prices, negotiated prices, and out-of-pocket costs often bearing little resemblance to one another.
What Manufacturers Consider at Launch
When a pharmaceutical company brings a new drug to market, the launch price reflects a mix of strategic and economic factors. For a first-in-class drug with no direct competitors, manufacturers typically use what’s called a skimming strategy: setting a high initial price to maximize revenue from the patients and insurers willing to pay for a novel treatment. As the drug matures and competitors enter the market, prices may come down. Older drugs nearing the end of their commercial life tend to shift toward lower pricing to maintain volume.
The cost of research and development plays a role in how companies justify these prices, though the relationship between R&D spending and any individual drug’s price is loose. A study published in JAMA Network Open estimated the mean cost of developing a single new drug at roughly $173 million (in 2018 dollars) for the drug itself. But most drug candidates fail before reaching patients. When the cost of those failures is folded in, the average rises to about $516 million. Add in the cost of capital (the money tied up for years before a product generates revenue), and the figure climbs to roughly $879 million. Estimates across the industry range from $314 million to $4.46 billion depending on the disease area, the data sources used, and modeling assumptions. Manufacturers point to these numbers when defending high prices, arguing they need to recoup investment and fund future research.
How Patents and Exclusivity Protect Prices
A new drug’s price stays high in large part because competition is legally blocked for years. U.S. patents last 20 years from the filing date, and since companies file patents early in development, the effective period of market protection after approval is shorter, often around 10 to 13 years. On top of patents, the FDA grants regulatory exclusivity periods that prevent generic or biosimilar competitors from entering the market even if no patent exists.
The length of exclusivity depends on the type of drug. A new chemical entity gets five years. Orphan drugs, which treat rare diseases affecting small patient populations, receive seven years. If a company conducts new clinical studies on an existing drug (for a new use, for instance), it earns three additional years. Pediatric exclusivity adds six months to all existing patents and exclusivity periods for a given ingredient. These protections stack and overlap in ways that can extend a manufacturer’s monopoly well beyond the original patent window. During that time, the manufacturer faces no price competition and has wide latitude to set and raise prices.
The Role of Middlemen
Between the manufacturer and the patient sits a chain of intermediaries, each of which affects the final price. Wholesalers buy drugs from manufacturers and distribute them to pharmacies. In 2022, wholesaler margins totaled $23.4 billion across the U.S. retail channel, representing about 6.3 percent of drug spending. Pharmacy margins added another $12.2 billion, or about 3.2 percent. These margins are relatively thin compared to what happens further up the chain.
Pharmacy benefit managers, or PBMs, are the most influential middlemen. They negotiate rebates from manufacturers on behalf of insurance plans, manage the lists of covered drugs (called formularies), and design the cost-sharing structures that determine what you pay at the counter. Rebates historically have represented roughly 5 percent of net drug spending, though this figure varies widely. For high-cost brand-name drugs in competitive therapeutic classes, rebates can be substantially larger because manufacturers compete to secure favorable placement on a PBM’s formulary.
The key tension is that rebates lower the net price paid by the insurance plan but don’t always reduce what you pay at the pharmacy. Your copay or coinsurance is often calculated based on the list price, not the discounted price the insurer actually pays. This means a drug with a high list price and a large rebate can still cost you more out of pocket than a lower-priced alternative.
How Insurance Design Shapes Your Cost
Most insurance plans use tiered copayment structures to steer you toward less expensive options. Generic drugs sit on the lowest tier with the smallest copay. Preferred brand-name drugs, typically those for which the PBM has negotiated a rebate, occupy the middle tier. Non-preferred brand-name drugs without rebates land on the highest tier, where copays can be significantly more. Some plans use coinsurance instead of flat copays, meaning you pay a percentage of the drug’s cost rather than a fixed dollar amount. For expensive specialty drugs, coinsurance can translate to hundreds or thousands of dollars per fill.
Manufacturer copay cards have become a common workaround. These cards, offered directly by drug companies, cover part or all of your deductible and copay for a specific brand-name medication. In a survey of patients using copay cards, 93 percent said the cards had moderate or high value in terms of monthly savings, and many reported they simply could not afford their medications without them. The catch is that copay cards can steer you toward expensive brand-name drugs when cheaper generics exist, since the card removes the price signal your insurance plan was designed to send. In response, many insurers have adopted “accumulator” programs that prevent copay card payments from counting toward your annual deductible or out-of-pocket maximum. Patients affected by accumulators report significant cost increases, sometimes hundreds of extra dollars per month, and research has linked these programs to lower prescription fill rates and higher rates of treatment discontinuation.
Value-Based Pricing
An increasingly discussed alternative to cost-plus or market-based pricing is value-based pricing, which ties a drug’s price to how much health benefit it delivers. In theory, a drug’s value equals the cost of the existing standard treatment plus or minus the additional clinical benefit the new drug provides. The factors considered include quality-of-life improvements, reduced hospitalizations, fewer disability days, gains in life expectancy, and broader societal benefits like allowing patients to return to work.
In practice, defining “value” is contested. Manufacturers emphasize innovation, scientific advancement, and the long-term benefits of breakthrough treatments. Payers focus on cost-effectiveness, asking whether the health gains justify the price compared to alternatives. Patient groups highlight unmet medical need and disease severity. Despite widespread discussion, cost-effectiveness remains one of the least consistently applied elements in drug pricing decisions, and no single value framework has become standard in the U.S.
Government Price Negotiation
For decades, the U.S. federal government did not directly negotiate drug prices for Medicare. That changed with the Inflation Reduction Act, which authorized Medicare to negotiate prices for certain high-cost drugs. The first cycle selected 10 drugs covered under Medicare Part D, with negotiated prices set to take effect on January 1, 2026. The law requires the Centers for Medicare and Medicaid Services to consider factors similar to value-based frameworks: the drug’s clinical benefit, its cost relative to alternatives, and its impact on the Medicare program.
This remains limited in scope. The negotiation program applies only to drugs that have been on the market for several years without generic competition and that account for high Medicare spending. The vast majority of drugs on the market are not subject to negotiation.
How Other Countries Handle It
Most other high-income countries use some form of price regulation that the U.S. does not. The most common approach is international reference pricing, where a government sets its maximum allowable price based on what other countries pay for the same drug. As of recent surveys, 25 of 28 European countries used some version of this system. Each country selects a “basket” of reference nations and benchmarks its prices against them.
Several U.S. legislative proposals have attempted to import this concept. The Prescription Drug Price Relief Act, for example, would cap U.S. prices at the median paid in Canada, the United Kingdom, France, Germany, and Japan. None of these broader proposals have become law, but they reflect a persistent gap: Americans routinely pay more for the same drugs than patients in peer countries, largely because the U.S. system relies more heavily on private negotiation than on government-set price ceilings.